Entero Therapeutics (NASDAQ:ENTO) Trading 5.2% Higher – Should You Buy?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) rose 5.2% during mid-day trading on Wednesday . The company traded as high as $5.03 and last traded at $4.69. 93,656 shares changed hands during trading, a decline of 97% from the average session volume of 2,798,922 shares. The stock had previously closed at $4.46.

Entero Therapeutics Stock Up 5.2%

The stock has a market cap of $7.45 million, a PE ratio of -2.78 and a beta of 1.19. The firm has a 50-day simple moving average of $4.29 and a 200-day simple moving average of $3.38.

Institutional Trading of Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics as of its most recent filing with the Securities and Exchange Commission. 12.30% of the stock is currently owned by institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.